Evidence map›Paper›PMID 30597261›Full record

ArticleInternational journal of pharmaceutics2019

Targeted inactivation of EPS8 using dendrimer-mediated delivery of RNA interference.

Quan Yuan, W Andrew Yeudall, Eunmee Lee, Hu Yang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Quan YuanDepartment of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA 23284, United States.
W Andrew YeudallDepartment of Oral Biology, Augusta University, Augusta, GA 30912, United States; Molecular Oncology and Biomarkers Program, Georgia Cancer Center, Augusta University, Augusta, GA 30912, United States.
Eunmee LeePhilips Institute for Oral Health Research, Virginia Commonwealth University, Richmond, VA 23298, United States.
Hu YangDepartment of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA 23219, United States; Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, United States; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, United States. Electronic address: hyang2@vcu.edu.
Virginia Commonwealth University · USAugusta University · US

Funding

EPS8 as a Driver of the Oral Cancer Initiating Cell Phenotype.R01DE024381 · NIDCR · VIRGINIA COMMONWEALTH UNIVERSITY · PI YEUDALL, WILLIAM ANDREW · 2014 to 2017
$1.3M
NIDCR NIH HHS R01 DE024381
6 · The paper itself

Abstract

We developed polyamidoamine dendrimers conjugated with epidermal growth factor (EGF) for use in receptor-mediated delivery of therapeutics to cancer cells. Here, we demonstrate the utility of this approach to inhibit proliferation and migration of head and neck squamous carcinoma cells through targeting of EPS8, a key regulator of squamous carcinoma growth and motility. Use of EGF-dendrimers to deliver siRNA or shRNA against EPS8 resulted in inhibition of cell growth and reduction in cell motility. Moreover, more profound repression of the target protein was obtained with repeat exposure to the targeting reagent, and was consistent with the altered biological properties. Thus, targeting of EPS8 can be achieved with EGF-conjugated dendrimers delivering EPS8-specific RNAi therapeutics, leading to a reduction in the malignant phenotype of cells.

Indexed as

Adaptor Proteins, Signal TransducingCell Line, TumorCell MovementDendrimersHumansRNA InterferenceRNA, Small InterferingAdaptor Proteins, Signal TransducingDendrimersEPS8 protein, humanRNA, Small InterferingDendrimerEGFROral cancerSignal transductionTargeted therapy

Identifiers

PMID30597261
PMCPMC10629616
OpenAlexW2907891968

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.